Novartis, PTC Therapeutics

PTC Therapeutics signs up to $2.9 billion licensing deal with Novartis
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug for a rare neurological disorder, sending its shares up about 18.5% in premarket trading on Monday.
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties.
Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological disorder called Huntington's disease, sending the U.S.-based biotech's shares up about 14% on Monday.
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing Phase II data in amyotrophic lateral sclerosis.
Novartis, PTC Ink Up-to-$2.9B Huntington’s Disease Collaboration
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license and collaboration agreement.
Novartis signs licensing deal worth up to $2.9B with PTC Therapeutics
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
PTC Therapeutics enters global license, collaboration agreement with Novartis
PTC Therapeutics (PTCT) announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Key Takeaways Shares of PTC Therapeutics soared Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.The deal gives Novartis global development,
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease, the companies said in separate Monday statements.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
FierceBiotech2d
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Business Insider21h
PTC Therapeutics price target raised to $32 from $26 at Citi
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, ...
ENDPOINTS NEWS2d
No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug
Novartis is returning to Huntington's disease with a $1 billion upfront bet, plus another $1.9 billion in biobucks, for ...
FierceBiotech7d
PTC axes utreloxastat program after phase 2 ALS failure
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...
6 Analysts Assess PTC: What You Need To Know
Throughout the last three months, 6 analysts have evaluated PTC PTC, offering a diverse set of opinions from bullish to ...
Business Insider2d
PTC Therapeutics: Strategic Partnerships and Financial Strength Drive Buy Rating
In a report released yesterday, Eric Joseph from J.P. Morgan maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price target of $62.00. Don't Miss our Black Friday Offers: ...
Stocktwits on MSN1d
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows
Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...